Healthcarewriter

Anti-GBM Disease total market size in the 7MM is expected to rise by 2030 with a CAGR of 22.2% during the study period (2018–2030), Estimates DelveInsight

Anti-Glomerular Basement Membrane (anti-GBM) disease (also known as Goodpasture syndrome or disease) is a rare but serious autoimmune disease that causes inflammation in the kidneys and lungs. Anti-GBM disease may affect only the kidneys; however, when it causes both kidney and lung disease, it is called Goodpasture’s syndrome. In anti-GBM disease, the immune system mistakenly makes “anti-GBM antibodies” that attack the lungs and kidneys, leading to bleeding and inflammation in the organs.

DelveInsight’s ‘Anti-GBM Disease Market Insights, Epidemiology, and Market Forecast 2030’ report delivers an in-depth understanding of the Anti-GBM disease, historical and forecasted epidemiology as well as the Anti-GBM Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

View Report: https://www.delveinsight.com/report-store/anti-glomerular-basement-membrane-anti-gbm-disease-market-insights

Some facts of Anti-GBM Disease Market are:

Delveinsight Estimates that the highest cases of Anti-GBM Disease in the 7MM were in United States, followed by the Germany, France, the United Kingdom, Italy, Spain, and Japan in 2020.
According to DelveInsight, In the United States, the total number of incident cases of Anti-GBM Disease was 532 cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.
According to DelveInsight, In the year 2020, the total incident cases of Anti-GBM Disease were 522 cases in EU-5 which are expected to grow during the study period, i.e., 2018–2030.
According to DelveInsight, In Japan, the total number of incident cases of Anti-GBM Disease was 63 cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.

To get detailed analysis of Anti-GBM Disease Market Report, Click Here @ https://www.delveinsight.com/sample-request/anti-glomerular-basement-membrane-anti-gbm-disease-market-insights

Scope of the Anti-GBM Disease Market Report

The report covers the descriptive overview of Anti-GBM, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
Comprehensive insight has been provided into the Anti-GBM epidemiology and treatment in the 7MM.
Additionally, an all-inclusive account of both the current and emerging therapies for Anti-GBM is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
A detailed review of the Anti-GBM market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Anti-GBM market.

Anti-GBM Disease Pipeline Drugs and Companies:

Idefirix (Imlifidase/HMed-IdeS): Hansa Biopharma
And Others

View Report: https://www.delveinsight.com/report-store/anti-glomerular-basement-membrane-anti-gbm-disease-market-insights

Expert Analysis:

Increase in the geriatric population play an important role in the development and exacerbation of Anti-GBM therapeutics market. Due to the growing pace of the elder population, the market of Anti-GBM is expected to increase in the forecast period.
Despite having lots of diagnosis options there are high chances of patients getting delay in diagnosis for Anti-GBM can be observed and the possible hurdles might be the lack of proper understanding of the disease (Anti-GBM).
Among the emerging therapies, Hansa Biopharma’s Idefirix (Imlifidase/HMed-IdeS), appears to be the only drug which have the potential to transform the Anti-GBM Disease market owing to impressive clinical data.

To get detailed analysis of Anti-GBM Disease Market Report, Click Here @ https://www.delveinsight.com/sample-request/anti-glomerular-basement-membrane-anti-gbm-disease-market-insights

Table of Contents:

1. Key Insights

2. Report Introduction

3. Anti-Glomerular Basement Membrane (anti-GBM) Disease Market Overview at a Glance

4. Executive Summary of Anti-Glomerular Basement Membrane (Anti-GBM) Disease

5. Epidemiology and Market Methodology

6. Disease Background and Overview

7. Diagnosis of Anti-GBM disease

8. Diagnostic Guidelines

9. Treatment of Anti-GBM disease

10. Treatment Guidelines

11. Epidemiology and Patient Population

12. Patient Journey Anti-GBM

13. Key Endpoints in Anti-GBM Disease Clinical Trials

14. Emerging Therapies

14.1. Idefirix (Imlifidase/HMed-IdeS): Hansa Biopharma

15. Anti-GBM Disease: 7 Major Market Analysis

16. Market Access and Reimbursement

17. KOL Views

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. Unmet Needs

22. Appendix

23. DelveInsight Capabilities

24. Disclaimer

View Report: https://www.delveinsight.com/report-store/anti-glomerular-basement-membrane-anti-gbm-disease-market-insights

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

May 1, 2022

Market Research Report, Pharmaceutical, Uncategorized

Anti-GBM Disease total market

Global Interbody Cages Market to Progress at a Substantial CAGR by 2026, Asserts DelveInsight

DelveInsight’s ‘Interbody Cages Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of Interbody Cages and the historical and forecasted Interbody Cages market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Some of the Interbody Cages Companies are

Aurora Spine, Inc.
B. Braun Melsungen AG
Benvenue Medical, Inc.
Ulrich Medicals USA
Prodorth
Orthofix International N.V.
Medtronic, plc
Zimmer Biomet, Inc.
NuVasive, Inc.
Johnson & Johnson (DePuy Synthesis)
And Many Others

View Report: https://www.delveinsight.com/report-store/interbody-cages-market

To know about the products by Interbody Cages companies, click here: https://www.delveinsight.com/sample-request/interbody-cages-market

Interbody cage Overview

Interbody cage is an artificial medical device, which is utilized in spinal fusion procedures to maintain foraminal height and decompression. The interbody cage is a large, hollow cylinder made up of metals such as titanium, carbon fiber, or allograft femur. The device is designed as a cage so that bone graft can be placed inside the hollow cylinder to allow a spinal fusion to occur between two vertebrae. Interbody cage is utilized to provide stability to the spine and the cervical region. The cages can be filled with autologous bone material to promote arthrodesis (artificial induction of joint ossification).

Key Highlights of the Interbody Cages MarketReport

The report covers the descriptive overview of Interbody Cages, explaining its applications, advantages, and limitations, etc.
Additionally, detailed profiles of the Key Companies operating in the market is provided, along with the market share of the Key 3-5 players.
A detailed review of Interbody Cages market; historical and forecasted market size is included in the report, covering global outreach.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Interbody Cages market.

View Report: https://www.delveinsight.com/report-store/interbody-cages-market

Scope of Interbody Cages Market Report:

Coverage: Global
Study Period: 2021-2026
Market Segmentation By Product Type – Lumbar Cage, Cervical Cage, Thoraco-lumbar Cage, Thoracic Cage and Others.
Market Segmentation By Geography – North America, Europe, Asia-Pacific, and Rest of the World
Key Dialysis Companies – Aurora Spine, Inc., B. Braun Melsungen AG, Benvenue Medical, Inc., Ulrich Medicals USA, Prodorth, Orthofix International N.V., Medtronic, plc, Zimmer Biomet, NuVasive, Johnson & Johnson (DePuy Synthesis), And Many Others
Porter’s Five Forces Analysis
Product Profiles
Case Studies
KOL’s Views
Analyst’s View

View Report: https://www.delveinsight.com/report-store/interbody-cages-market

To know details about the scope of Interbody Cages market report, click here: https://www.delveinsight.com/sample-request/interbody-cages-market

Table of Content

1. Interbody Cages Market Report Introduction

2. Interbody Cages Market Executive summary

3. Regulatory and Patent Analysis

4. Interbody Cages Market Key factors analysis

5. Interbody Cages Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Interbody Cages Market

7. Interbody Cages Market layout

8. Interbody Cages Global Company Share Analysis – Key 3-5 Companies

9. Interbody Cages Company and Product Profiles

10. PROJECT APPROACH

11. KOL Views

12. DelveInsight Capabilities

13. Disclaimer

View Report: https://www.delveinsight.com/report-store/interbody-cages-market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

April 30, 2022

Market Research Report, Pharmaceutical, Uncategorized

Interbody Cages Market

Anaphylaxis Market Size, Epidemiology Facts, Key Players, Therapies, and Market Report 2032

Anaphylaxis is an acute, potentially life-threatening, generalized, or systemic allergic reaction that is mediated by the degranulation of mast cells and basophils. The condition usually develops suddenly and gets worse very quickly.

DelveInsight’s “Anaphylaxis Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Anaphylaxis, historical and forecasted epidemiology as well as the Anaphylaxis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Anaphylaxis Market report provides an edge while developing business strategies, by understanding trends shaping and driving the global Anaphylaxis market. A detailed review of the historical and forecasted Anaphylaxis market is included in the report, covering drug outreach in the 7MM.

Some of the key highlights of the Anaphylaxis Market Report

A study titled “The Epidemiology of Anaphylaxis”, wherein the lifetime prevalence of anaphylaxis was estimated at 0.05–2% in the USA and approximately 3% in Europe. The study also mentioned that in UK, of patients presenting to paramedics and first aides estimated 0.2% of emergency cases due to anaphylaxis.
Biphasic anaphylaxis is a recurrence of anaphylaxis after appropriate treatment. It happens with no additional exposure to the allergen and strikes after the patient has survived the initial attack.
Anaphylaxis develops rapidly, usually reaching peak severity within 5 to 30 minutes, and may, rarely, last for several days.
Approximately 1 in 5 admissions to hospitals in England due to allergies were for an anaphylactic reaction (4070 out of 20,318). This was an increase of 9.9% on the same period in the previous year. The NICE CG134 guideline reported an available UK estimate that about 1 in 1,333 of the population of England had experienced anaphylaxis at some point in their lives. However, a systematic review published in 2013 estimated that 1 in 300 people in Europe were affected by anaphylaxis at some point in their lives

View Report: https://www.delveinsight.com/report-store/anaphylaxis-market

Get Access to a Free Copy of Our Latest Sample Report @ https://www.delveinsight.com/sample-request/anaphylaxis-market

Anaphylaxis Epidemiology Insights

The lifetime prevalence of anaphylaxis has been estimated at 1.6% to 5.1%. Medications and stinging insects are the leading triggers in adults, with foods and stinging insects the most frequently implicated triggers in children and adolescents. Food allergy impacts 8% to 11% of children and adults in the United States, while adverse drug reactions (ADRs) affect up to 10% of the population (and 20% of hospitalized patients), with hypersensitivity reactions (HSRs) accounting for 10% of all ADRs.

Anaphylaxis Epidemiology Segmentation in the 7MM (2019-2032)

Anaphylaxis Prevalent Population
Anaphylaxis Diagnosed and Treatable Cases
Anaphylaxis Trigger-specific Population

View Report: https://www.delveinsight.com/report-store/anaphylaxis-market

Anaphylaxis Market Insights

Anaphylaxis is variable and unpredictable. It may be mild and resolve spontaneously due to endogenous production of compensatory mediators or it may be severe and progress within minutes to respiratory or cardiovascular compromise and death. The treatment for anaphylaxis majorly includes the use of epinephrine to prevent the possible progression to life-threatening manifestations. When the patient is admitted at the hospital, they might receive glucocorticoid and antihistamines intravenously. These medications help to reduce inflammation in the air passages, improving your ability to breathe. They may also be given beta-agonists such as albuterol to make breathing easier and may also receive supplemental oxygen to help the body get the oxygen it needs.

Anaphylaxis Symptoms

The symptoms include feeling lightheaded or faint, breathing difficulties – such as fast, shallow breathing, wheezing, fast heartbeat, clammy skin, confusion and anxiety, collapsing or losing consciousness. There may also be other allergy symptoms, including an itchy, raised rash (hives), feeling or being sick, swelling (angioedema) or stomach pain.

Anaphylaxis Diagnosis

A blood test to measure the amount of a certain enzyme (tryptase) that can be elevated up to three hours after anaphylaxis is analyzed. In addition, the patient is tested for allergies with skin tests or blood tests to help determine the trigger. The differential diagnosis for anaphylaxis includes respiratory difficulty or circulatory collapse, including vasovagal reactions, globus hystericus, status asthmaticus, foreign body aspiration, pulmonary embolism, epiglottitis, myocardial infarction, carcinoid syndrome, hereditary angioedema, pheochromocytoma and other. Upper airway obstruction, bronchospasm, abdominal cramps, pruritus, urticaria and angioedema are absent in vasovagal reactions. Pallor, syncope, diaphoresis and nausea usually indicate a vaso-vagal reaction but may occur in either condition.

View Report: https://www.delveinsight.com/report-store/anaphylaxis-market

View Detailed Research Report Here @ https://www.delveinsight.com/sample-request/anaphylaxis-market

Anaphylaxis Companies

Pfizer
Adamis Pharmaceuticals
Aquestive Therapeutics
Wyss Institute, and others

Anaphylaxis Drugs

AbbieSense technology
AQST-109
AQST-108
Symjepi
EpiPen and EpiPen Jr, and others

View Report: https://www.delveinsight.com/report-store/anaphylaxis-market

Anaphylaxis Emerging Therapy Assessment

The pipeline of Anaphylaxis possess potential key player, such as Aquestive Therapeutics, Wyss Institute and others. The dynamics of Anaphylaxis market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise of efficient treatment options. The launch of emerging therapies is expected during the forecast period of 2021–2030.

Table of content

1. Key Insights

2. Executive Summary

3. Competitive Intelligence Analysis

4. Market Overview at a Glance

5. Disease Background and Overview

6. Patient Journey

7. Anaphylaxis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Anaphylaxis Treatment

11. Marketed Products

12. Emerging Therapies

13. Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

View Report: https://www.delveinsight.com/report-store/anaphylaxis-market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Polypoidal Choroidal Vasculopathy Market

April 30, 2022

Market Research Report, Pharmaceutical, Uncategorized

Angioedema Market, Epidemiology, Treatment, Pipeline, Drugs, Companies and Competitive Analysis by DelveInsight

Angioedema is swelling underneath the skin. It’s usually a reaction to a trigger, such as a medicine or something you’re allergic to. It is not normally serious, but it can be a recurring problem for some people and can very occasionally be life-threatening if it affects breathing.

DelveInsight’s “Angioedema Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Angioedema, historical and forecasted epidemiology as well as the Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of Angioedema Market Report are:

HAE in the US has been observed with the maximum number of diagnosed cases in the age-group 17 to below 65 years, followed by those who belong to the age-group 12 to less than 17 years. DelveInsight’s analysts have estimated that there were 882 cases diagnosed for the age group 17 to below 65 years in 2017, among the US population, which is predicted to increase consistently throughout the study period.
Among the European countries, France had the highest prevalent population of 1,346 cases, followed by the UK which had prevalent population of 1,301 in 2017.
Type 1 HAE (98.73%) accounted for the majority of Chinese HAE patients, while no type 3 HAE patient has been diagnosed in China to date (Liu et al, 2019).
According to DelveInsight’s analysis, HAE is more prominent in females in comparison to males.

View Report: https://www.delveinsight.com/report-store/angioedema-market

To know more details about Angioedema Market Report, Click here: https://www.delveinsight.com/sample-request/angioedema-market

Scope of the Angioedema Market Report

The report covers the descriptive overview of Angioedema, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Angioedema epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Angioedema is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of the Angioedema market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Angioedema market

View Report: https://www.delveinsight.com/report-store/angioedema-market

To know more details of Angioedema Market Report, Click here: https://www.delveinsight.com/report-store/angioedema-market

Some of Angioedema Drugs are:

Lanadelumab
C1 inhibitor concentrate (C1-esteraseremmer-N)
Icatibant
Omalizumab
KVD824
And Many Others

Some of the Angioedema Companies are:

Takeda
Shire Pharmaceuticals
Prothya Biosolutions
Novartis
KalVista Pharmaceuticals
And Many Others

View Report: https://www.delveinsight.com/report-store/angioedema-market

To know more details about Angioedema Pipeline drugs and Therapies, Click here: https://www.delveinsight.com/sample-request/angioedema-market

Table of Contents:

1. Key Insights

2. Executive Summary of Angioedema

3. Competitive Intelligence Analysis for Angioedema

4. Angioedema: Market Overview at a Glance

5. Angioedema: Disease Background and Overview

6. Patient Journey

7. Angioedema Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Angioedema Unmet Needs

10. Key Endpoints of Angioedema Treatment

11. Angioedema Marketed Products

12. Angioedema Emerging Therapies

13. Angioedema: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Angioedema

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

View Report: https://www.delveinsight.com/report-store/angioedema-market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

April 30, 2022

Market Research Report, Pharmaceutical, Uncategorized

Angioedema Market

Anal Cancer Market, Epidemiology, Pipeline, Drugs, Companies and Competitive Analysis by DelveInsight

Anal cancer is a disease in which malignant (cancer) cells form in the tissues of the anus. Most anal cancers are related to human papillomavirus (HPV) infection. Signs of anal cancer include bleeding from the anus or rectum or a lump near the anus.

DelveInsight’s “Anal Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Anal Cancer, historical and forecasted epidemiology as well as the Anal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

View Report: https://www.delveinsight.com/report-store/anal-cancer-market

Some facts of Anal Cancer Market Report are:

In the general population, anal cancer is uncommon, with age-standardised incidence rates mostly between 1 and 2 per 100000 per year.
The rate of new cases of anal cancer was 1.9 per 100,000 men and women per year. The death rate was 0.3 per 100,000 men and women per year. These rates are age-adjusted and based on 2015–2019 cases and deaths.
Approximately 0.2 percent of men and women will be diagnosed with anal cancer at some point during their lifetime, based on 2017–2019 data.
In 2019, there were an estimated 74,752 people living with anal cancer in the United States.

Anal Cancer Symptoms

Anal cancer signs and symptoms include:

Bleeding from the anus or rectum
Pain in the area of the anus
A mass or growth in the anal canal
Anal itching

View Report: https://www.delveinsight.com/report-store/anal-cancer-market

Scope of the Anal Cancer Market Report

The report covers the descriptive overview of Anal Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Anal Cancer epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Anal Cancer is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of the Anal Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Anal Cancer market

To get detailed List of Anal Cancer Drugs in pipeline, Request for Sample Report: https://www.delveinsight.com/sample-request/anal-cancer-market

Some of Anal Cancer Drugs are:

Pembrolizumab
MPDL3280A
ADXS11-001
BMX-001
RTX-321
cidofovir
Bevacizumab
And Many Others

View Report: https://www.delveinsight.com/report-store/anal-cancer-market

Some of Anal Cancer Companies Covered:

Merck
Roche
Advaxis, Inc.
BioMimetix JV, LLC
Rubius Therapeutics
The Emmes Company
Genentech
And Many Others

To get detailed information of Anal Cancer Companies in pipeline, Request for Sample Report: https://www.delveinsight.com/sample-request/anal-cancer-market

Table of Content:

1. Key Insights

2. Executive Summary of Anal Cancer

3. Competitive Intelligence Analysis for Anal Cancer

4. Anal Cancer: Market Overview at a Glance

5. Anal Cancer: Disease Background and Overview

6. Patient Journey

7. Anal Cancer Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Anal Cancer Unmet Needs

10. Key Endpoints of Anal Cancer Treatment

11. Anal Cancer Marketed Products

12. Anal Cancer Emerging Therapies

13. Anal Cancer: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Anal Cancer

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Related Reports:

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Contact us
Ankit Nigam
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/
Connect With Us at:
LinkedIn | Facebook | Twitter

April 26, 2022

Market Research Report, Pharmaceutical, Uncategorized

Anal Cancer Market

Advanced Recurrent Ovarian Cancer Market, Epidemiology, Pipeline, Drugs, Companies and Competitive Analysis by DelveInsight

Ovarian cancer is the most lethal gynaecological malignancy that presents at an advanced stage in 75% of patients. Ovarian cancer is predominantly a disease of older, postmenopausal women with the majority (>80%) of cases being diagnosed in women over 50 years. The exact cause of ovarian cancer remains unknown, but many associated risk factors have been identified. A woman’s reproductive history appears to contribute significantly to her lifetime risk of ovarian cancer. The three major types of ovarian cancer are epithelial, accounting for 90% of cases, germ cell (3%), and sexcord-stromal (2%). Epithelial cancers are further subdivided into serous (52%), endometrioid (10%), mucinous (6%), and clear cell (6%) tumours.

DelveInsight’s “Advanced Recurrent Ovarian Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Advanced Recurrent Ovarian Cancer, historical and forecasted epidemiology as well as the Advanced Recurrent Ovarian Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

View Report: https://www.delveinsight.com/report-store/advanced-recurrent-ovarian-cancer-market

Some facts of Advanced Recurrent Ovarian Cancer Market Report:

According to a study by J.A. Ledermann et al., titled, “Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”, the estimated number of new ovarian cancer cases in Europe in 2012 was 65,538 with 42,704 deaths.
There is variation in the incidence rate across the continent with a higher incidence in northern European countries. In the USA, there were ∼20,400 newly diagnosed cases and 14,400 deaths in 2009.
Ovarian cancer is the fifth most common type of cancer in women and the fourth most common cause of cancer death in women. The estimated lifetime risk for a woman developing ovarian cancer is about one in 54.
According to the American Cancer Society, approximately 20% of ovarian cancer cases, particularly high-grade serous tumours, are estimated to be due to inherited mutations that confer elevated risk, the majority from BRCA1 and BRCA2.

Some of Advanced Recurrent Ovarian Cancer Pipeline Drugs are

Bevacizumab
MM-121
OTL38
2X-121
PX-Survivac
Oregovomab
HPN536
PRGN-3005 UltraCAR-T
And Many Others

To get detailed List of Advanced Recurrent Ovarian Cancer Drugs in pipeline, Request for Sample Report: https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-market

Key Benefits of Advanced Recurrent Ovarian Cancer Market Report:

The report covers the descriptive overview of Advanced Recurrent Ovarian Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Advanced Recurrent Ovarian Cancer epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Advanced Recurrent Ovarian Cancer is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of the Advanced Recurrent Ovarian Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Advanced Recurrent Ovarian Cancer market

View Report: https://www.delveinsight.com/report-store/advanced-recurrent-ovarian-cancer-market

Some of Advanced Recurrent Ovarian Cancer Companies:

MedImmune LLC
Merrimack Pharmaceuticals
On Target Laboratories
Oncology Venture
ImmunoVaccine Technologies
OncoQuest
Harpoon Therapeutics
Precigen
And Many Others

To get detailed information of Advanced Recurrent Ovarian Cancer Companies in pipeline, Request for Sample Report: https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-market

Table of Contents

1. Key Insights

2. Executive Summary of Advanced Recurrent Ovarian Cancer

3. Competitive Intelligence Analysis for Advanced Recurrent Ovarian Cancer

4. Advanced Recurrent Ovarian Cancer: Market Overview at a Glance

5. Advanced Recurrent Ovarian Cancer: Disease Background and Overview

6. Patient Journey

7. Advanced Recurrent Ovarian Cancer Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Advanced Recurrent Ovarian Cancer Unmet Needs

10. Key Endpoints of Advanced Recurrent Ovarian Cancer Treatment

11. Advanced Recurrent Ovarian Cancer Marketed Products

List to be continued in report

12. Advanced Recurrent Ovarian Cancer Emerging Therapies

List to be continued in report

13. Advanced Recurrent Ovarian Cancer: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Advanced Recurrent Ovarian Cancer

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

View Report: https://www.delveinsight.com/report-store/advanced-recurrent-ovarian-cancer-market

Other Reports:

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Contact us
Ankit Nigam
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/
Connect With Us at:
LinkedIn | Facebook | Twitter

April 26, 2022

Market Research Report, Pharmaceutical, Uncategorized

Advanced Recurrent Ovarian Cancer Market

Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis Pipeline Insight, Therapeutic Assessment, Unmet Needs and Impact of Drugs

Hepatocellular carcinoma is a common type of liver cancer and mostly occurs in individuals with chronic liver cirrhosis caused by HBV and HVC infection. Advanced hepatocellular carcinoma with CPB Liver Cirrhosis is most severe form. The cancer begins in hepatocytes and is due to mutations in DNA of liver cells. Excessive alcohol consumption, non-alcoholic fatty liver disease, and other risk factors are likely to increase the chances of developing liver cancer. Signs and Symptoms can include upper abdominal pain, unexplained weight loss, nausea, jaundice, fatigue, and chalky stools.

The “Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Pipeline Insight, 2022” drug pipelines has been added to DelveInsight’s offering.

This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Advanced Hepatocellular Carcinoma with CPB liver cirrhosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

View Report: https://www.delveinsight.com/report-store/advanced-hepatocellular-carcinoma-with-cpb-liver-cirrhosis-pipeline-insight

The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Hepatocellular Carcinoma with CPB liver cirrhosis pipeline landscape is provided which includes the disease overview and Advanced Hepatocellular Carcinoma with CPB liver cirrhosis treatment guidelines.

The assessment part of the report embraces, in depth Advanced Hepatocellular Carcinoma with CPB liver cirrhosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Hepatocellular Carcinoma with CPB liver cirrhosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

To Know More About Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis Pipeline Report, Request for a Sample Report: https://www.delveinsight.com/sample-request/advanced-hepatocellular-carcinoma-with-cpb-liver-cirrhosis-pipeline-insight

There are approx. 3+ key companies which are developing the therapies for Advanced Hepatocellular Carcinoma with CPB liver cirrhosis. The companies which have their Advanced Hepatocellular Carcinoma with CPB liver cirrhosis drug candidates in the most advanced stage, i.e. phase II include, Can-Fite Biophama.

The Advanced Hepatocellular Carcinoma with CPB liver cirrhosis pipeline report covers around 3+ products under different phases of clinical development:

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

View Report: https://www.delveinsight.com/report-store/advanced-hepatocellular-carcinoma-with-cpb-liver-cirrhosis-pipeline-insight

Key Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Pipeline Report Insights

Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Key Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Pipeline Report Assessments

Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

View Report: https://www.delveinsight.com/report-store/advanced-hepatocellular-carcinoma-with-cpb-liver-cirrhosis-pipeline-insight

Current Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Treatment Scenario and Emerging Therapies:

How many companies are developing Advanced Hepatocellular Carcinoma with CPB liver cirrhosis drugs?
How many Advanced Hepatocellular Carcinoma with CPB liver cirrhosis drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Hepatocellular Carcinoma with CPB liver cirrhosis?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Advanced Hepatocellular Carcinoma with CPB liver cirrhosis therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Advanced Hepatocellular Carcinoma with CPB liver cirrhosis and their status?
What are the key designations that have been granted to the emerging drugs?

To Know More about Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis Treatment Scenario, Request for a Sample Report: https://www.delveinsight.com/sample-request/advanced-hepatocellular-carcinoma-with-cpb-liver-cirrhosis-pipeline-insight

Key Topics Covered:

Executive Summary
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis – Analytical Perspective
In-depth Commercial Assessment
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Collaboration Deals
Mid Stage Products (Phase II)
Namodenoson: Can-Fite Biopharma
Early Stage Products (Phase I)
Inactive Products
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Key Companies
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Key Products
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis – Unmet Needs
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis – Market Drivers and Barriers
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis – Future Perspectives and Conclusion
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Analyst Views
Advanced Hepatocellular Carcinoma with CPB liver cirrhosis Key Companies

View Report: https://www.delveinsight.com/report-store/advanced-hepatocellular-carcinoma-with-cpb-liver-cirrhosis-pipeline-insight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Related Reports:

April 26, 2022

Market Research Report, Pharmaceutical, Uncategorized

Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis Pipeline

Adrenocortical Carcinoma Treatment Market Size, Epidemiology, Drugs Pipeline, Market Analysis and Companies by DelveInsight

Adrenocortical Carcinoma (ACC) is rare cancerthat originates in the outer layer of the adrenal gland. ACC is also called cancer of the adrenalcortex. A tumor of the adrenal cortex may be functioning (produces surplus hormones thanusual) or nonfunctioning (does not produce surplus hormones than usual). Mostadrenocortical tumors are functioning. The hormones made by functioning tumors may cause sure signs or symptoms of the disease;the common symptoms caused by ACC include a lump in the abdomen, pain in the abdomenor back, and feeling of fullness in the abdomen.

DelveInsight’s “Adrenocortical Carcinoma Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Adrenocortical Carcinoma, historical and forecasted epidemiology as well as the Adrenocortical Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of Adrenocortical Carcinoma Market Report

According to the retrospective review conducted by Aspinall et al. titled “How is Adrenocortical Cancerbeing Managed in the UK?,” the incidence of ACC is 0.5‒2 per million per year.
According to the study by Johanssen et al. titled “Deficits in the Management of Patients With Adrenocortical Carcinoma in Germany,” the incidence of ACC is one per million population, and females are more frequently affected than males, with a female:male ratio of 1.5 : 1.
As per the article by Libé et al. titled “Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment,” the incidence of ACC are 0.7‒2 cases per million population per year. It is reported to be more commonplace females (55–60%) than males.
As per the article by Hammer et al. titled “Adrenal Cortical Carcinoma,” ACC has an incidence of less than one per million per year with female dominance and peak occurrence in the 4th‒5th decade of life. Patients present in one of three ways, symptoms of hormone excess (40%), abdominal pain/fullness or flank pain (40%), or as an incidental finding as part of an unrelated workup (20%).
According to Wang et al. (2017), Adrenocortical Carcinoma is more common in females than males.

To know more the Adrenocortical Carcinoma Report. Request for sample page here @ https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-market

Scope of the Adrenocortical Carcinoma Market Report

The report covers the descriptive overview of Adrenocortical Carcinoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Adrenocortical Carcinoma epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Adrenocortical Carcinoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of the Adrenocortical Carcinoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Adrenocortical Carcinoma market

Some of Adrenocortical Carcinoma Companies are:

Exelixis
Enterome
And Many Others

Adrenocortical Carcinoma Therapies are:

Cabozantinib
EO2401
And Many Others

To know about the Adrenocortical Carcinoma pipeline analysis and key companies. Request for sample page here @ https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-market

Table of Contents:

1. Key Insights

2. Executive Summary of Adrenocortical Carcinoma

3. Competitive Intelligence Analysis for Adrenocortical Carcinoma

4. Adrenocortical Carcinoma: Market Overview at a Glance

5. Adrenocortical Carcinoma: Disease Background and Overview

6. Patient Journey

7. Adrenocortical Carcinoma Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Adrenocortical Carcinoma Unmet Needs

10. Key Endpoints of Adrenocortical Carcinoma Treatment

11. Adrenocortical Carcinoma Marketed Products

List to be continued in report

12. Adrenocortical Carcinoma Emerging Therapies

List to be continued in report

13. Adrenocortical Carcinoma: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Adrenocortical Carcinoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

DelveInsight’s Competitive Intelligence Service includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach.

Some of Newly Launched Report:

Latest Blogs:

About Delveinsight:

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/

Connect With Us at:

LinkedIn | Facebook | Twitter

April 13, 2022

Market Research Report, Pharmaceutical

Adrenocortical Carcinoma, Adrenocortical Carcinoma Market, Adrenocortical Carcinoma Treatment, Adrenocortical Carcinoma Treatment Market

Antiphospholipid Syndrome (APS) Market Size, Share, Trends, Growth, Key Companies, Emerging Drugs and Epidemiology Forecast

Antiphospholipid Syndrome (APS) is an autoimmune disorder in which the immune system misguidedly creates antibodies that make one’s blood substantially more likely to clot. It is also known as Hughes syndrome or lupus anticoagulant syndrome. Those with APS make abnormal proteins known as antiphospholipid autoantibodies (aPL) in the blood. This causes blood to flow improperly and can prompt to dangerous clotting in arteries and veins, problems for a developing fetus, and pregnancy miscarriage.

Currently, there is no cure for APS, however, standard initial treatment involves a combination of blood-thinning medications. The most common are heparin and warfarin. Heparin is fast-acting and delivered via injections.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/antiphospholipid-syndrome-aps-market

DelveInsight’s “Antiphospholipid Syndrome (APS) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Antiphospholipid Syndrome (APS), historical and forecasted epidemiology as well as the Antiphospholipid Syndrome (APS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Antiphospholipid Syndrome (APS) market report also covers emerging drugs, current treatment practices, Antiphospholipid Syndrome (APS) market size and share of the individual therapies, current and forecasted Antiphospholipid Syndrome (APS) Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Antiphospholipid Syndrome (APS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Antiphospholipid Syndrome (APS) Market Key Facts

To estimate the annual incidence and prevalence of and frequency of mortality associated with APS, Duarte-García et al. (2019) conducted a population-based study. For that, an inception cohort of patients with incident APS in 2000–2015 from a geographically well-defined population was identified based on comprehensive individual medical records review. The investigators estimated the prevalence of 50 per 100,000 population for APS.
According to the American College of Rheumatology, Antiphospholipid antibodies are present in 15–20% of all cases of deep vein thrombosis (blood clots) and one-third of new strokes occurring in people under the age of 50.
According to American College of Rheumatology (2021) it was reported that antiphospholipid antibody syndrome affects women five times more commonly than men.
According to a study conducted by García et. al. (2019), the annual estimated prevalence of antiphospholipid antibody syndrome was 50 (95% CI 42–58) per 100,000 population.
According to a study by D’Cruz et. al. (2019), prevalence in the UK peaked at 50 (95% CI 49 – 55) in females in 2011 and 9.8 (95% CI 8.6 – 11.1) per 100,000 in males in 2012.
According to a study by Radin et. al. (2020), the prevalence cases of Antiphospholipid antibody syndrome in Italy are 40-50 cases per 100,000 persons and the diagnosis rate of Antiphospholipid antibody syndrome in Italy were 63% in aged of ≤50 years, 39% ≤40 years, and 18% ≤30 years.
According to an article by American College of Rheumatology (2021), it was reported that Antiphospholipid antibody syndrome affects women 5 times more commonly than men.

Key Benefits of Antiphospholipid Syndrome (APS) Market Report

Antiphospholipid Syndrome (APS) market report provides an in-depth analysis of Antiphospholipid Syndrome (APS) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Antiphospholipid Syndrome (APS) market report will help in developing business strategies by understanding the Antiphospholipid Syndrome (APS) Market trends & developments, key players, and future market competition that will shape and drive the Antiphospholipid Syndrome (APS) market in the upcoming years.
The Antiphospholipid Syndrome (APS) market report covers Antiphospholipid Syndrome (APS) market growth and current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Antiphospholipid Syndrome (APS) patient population, market drivers & barriers, Unmet Needs, market opportunities, comparative analysis of pipeline products with detailed clinical profiles, and other factors.

Antiphospholipid Syndrome (APS) Market

The Antiphospholipid Syndrome (APS) market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Antiphospholipid Syndrome (APS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

The report gives a thorough detail of Antiphospholipid Syndrome (APS) market trends and shares analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.

Antiphospholipid Syndrome (APS) Epidemiology

The Antiphospholipid Syndrome (APS) epidemiology section covers insights about historical and current Antiphospholipid Syndrome (APS) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted Antiphospholipid Syndrome (APS) epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Antiphospholipid Syndrome (APS) Drugs Uptake and Key Market Players

The Antiphospholipid Syndrome (APS) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Antiphospholipid Syndrome (APS) market or expected to get launched in the market during the study period. The analysis covers Antiphospholipid Syndrome (APS) market uptake by drugs; patient uptake by therapies; and sales of each drug.

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Get FREE sample copy at:
https://www.delveinsight.com/sample-request/antiphospholipid-syndrome-aps-market

Table of Content

Key Insights
Executive Summary
Antiphospholipid Syndrome (APS) Competitive Intelligence Analysis
Antiphospholipid Syndrome (APS) Market Overview at a Glance
Antiphospholipid Syndrome (APS) Disease Background and Overview
Antiphospholipid Syndrome (APS) Patient Journey
Antiphospholipid Syndrome (APS) Epidemiology and Patient Population
Antiphospholipid Syndrome (APS) Treatment Algorithm, Current Treatment, and Medical Practices
Antiphospholipid Syndrome (APS) Unmet Needs
Key Endpoints of Antiphospholipid Syndrome (APS) Treatment
Antiphospholipid Syndrome (APS) Marketed Products
Antiphospholipid Syndrome (APS) Emerging Therapies
Antiphospholipid Syndrome (APS) Seven Major Market Analysis
Attribute Analysis
Antiphospholipid Syndrome (APS) Market Outlook (7 major markets)
Antiphospholipid Syndrome (APS) Access and Reimbursement Overview
KOL Views on the Antiphospholipid Syndrome (APS) Market.
Antiphospholipid Syndrome (APS) Market Drivers
Antiphospholipid Syndrome (APS) Market Barriers
Appendix
DelveInsight Capabilities
Disclaimer

*The table of contents is not exhaustive; the final content may vary.

Related Reports
Antiphospholipid Syndrome (APS) Epidemiology Forecast
DelveInsight’s Antiphospholipid Syndrome (APS) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Antiphospholipid Syndrome (APS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Antiphospholipid Syndrome (APS) Pipeline Insights
Antiphospholipid Syndrome (APS) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Antiphospholipid Syndrome (APS) market.

Other Reports

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Contact us
Ankit Nigam
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/
Connect With Us at:
LinkedIn | Facebook | Twitter

Get Free Sample Copy of Report at:
https://www.delveinsight.com/sample-request/antiphospholipid-syndrome-aps-market

April 13, 2022

Market Research Report, Pharmaceutical

Antiphospholipid Syndrome, Antiphospholipid Syndrome (APS), Antiphospholipid Syndrome (APS) Market, Antiphospholipid Syndrome Market

Alopecia Areata Treatment Market Size, Epidemiology, Drugs Pipeline, Market Analysis and Companies by DelveInsight

Alopecia Areata (AA), an autoimmune skin disorder, in which the hair follicles get damaged by a faulty immune system. This faultiness causes the immune system to attack its own body, thus disrupting hair follicles and new hair formation. Biopsies performed have clearly shown the immune lymphocytes travelling in the hair bulbs of the hair follicle. The condition can lead to extreme hair loss in aggravated stages from the entire body, known as Alopecia universalis or it can lead to overall loss of hair from the scalp area, also called Alopecia Totalis.

DelveInsight’s “Alopecia Areata Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Alopecia Areata Symptoms

Patchy hair loss
Inflammation of the hair follicles
Cadaver hairs
White spots and lines appear
Pinpoint dents appear

Request for Free Sample Report: https://www.delveinsight.com/sample-request/alopecia-areata-market

Some facts of Alopecia Areata Market Report:

According to the Chantal Bolduc et al., 2018, the prevalence of alopecia areata (AA) in the general population is estimated to be 0.1–0.2%. The lifetime risk of developing alopecia areata is estimated to be 1.7%. All races are affected equally by alopecia areata and no increase in prevalence has been found in a particular ethnic group.
As per the study conducted by Alexandra C. Villasante Fricke et al. in 2015, the scalp is the most common site of involvement, with or without involvement of other body sites (such as the eyebrows, eyelashes, and beard). Specifically, the most common site was the occipital region, involved in 38.4% of males and 33.4% of females. Upon first presentation, 58% of adult patients had patchy hair loss with less than half the scalp involved. On the other hand, in children, 80–85% had mild-to-moderate hair loss involving less than half the scalp.
As per the National Organization of Rare Disease, alopecia areata is most common among the children and approximately 2.5 million people are suffering from alopecia areata in the United States.
As per Herbert Pratt et al. 2017, alopecia areata affects approximately two percent of the general population at some point during their lifetime
According to the National Alopecia Areata Foundation, approximately 6.8 million people in the United States and 147 million worldwide have or will develop alopecia areata at some point in their lives.
As per Alexandra C Villasante Fricke et al., 2015, patients with AA experience their first onset of AA by age 40 years in 82.6–88% of patients and by age 20 years in 40.2% of patients. The mean age of onset has been reported as between 25.2 and 36.3 years. In children, the mean age of onset has been reported as between ages 5 and 10 years.

Download Free Sample Report: https://www.delveinsight.com/sample-request/alopecia-areata-market

Alopecia Areata Treatment Market

The treatments commonly prescribed to AA patients include Injections, Oral, Topical Treatments and Light therapy.

Alopecia Areata Injections:

Steroid injections are commonly used in the treatment of AA, mainly for bald and patchy areas on the scalp. Steroidal injections are injected on the bare part of the affected area. Although it does not stop the hair fall, but effectively helps in regeneration of hair. The treatment is to be repeated in every one to two months.

Alopecia Areata Oral Treatments:

Cortisone tablets are majorly recommended for severe forms of AA. However, cortisone causes major side effects as well. Immunosuppressants such as methotrexate and cyclosporine are also recommended. They work by creating an obstruction for the immune system, but they cannot be ingested for prolonged periods due to serious side effects such as lymphoma, kidney and liver damages etc.

Alopecia Areata Topical Treatments:

Many types of topical treatments are rubbed on the scalp area and other regions of the body including eyebrows and beard. These involve Minoxidil (Rogaine), Anthralin (Dritho-Scalp), clobetasol (Impoyz), Diphencyprone etc.

Alopecia Areata Light Therapy:

This form of therapy uses a combination of psoralens and Ultra-violet light to treat AA.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/alopecia-areata-market

Some of Alopecia Areata Companies are:

Pfizer
Suzhou Zelgen Biopharmaceuticals
Eli Lilly and Company
Incyte Corporation
Aclaris Therapeutics
Legacy Healthcare
Concert Pharmaceuticals
LEO Pharma
Bristol-Myers Squibb
And Many Others

Alopecia Areata Therapies are:

PF-06651600
Jaktinib
Baricitinib
ATI-502
Abatacept
LH-8
LEO 124249
CTP-543
And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/alopecia-areata-market

Table of Contents:

1. Key Insights

2. Executive Summary of Alopecia Areata

3. Competitive Intelligence Analysis for Alopecia Areata

4. Alopecia Areata: Market Overview at a Glance

4.1. Alopecia Areata Total Market Share (%) Distribution in 2018

4.2. Alopecia Areata Total Market Share (%) Distribution in 2030

5. Alopecia Areata: Disease Background and Overview

6. Patient Journey

7. Alopecia Areata Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Alopecia Areata Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Alopecia Areata: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Alopecia Areata

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Related Reports:

About Delveinsight:

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Know More about our competitive intelligence services.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/

April 13, 2022

Market Research Report, Pharmaceutical, Uncategorized

Alopecia Areata, Alopecia Areata Market, Alopecia Areata Treatment, Alopecia Areata Treatment Market